Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chu, Yeonjeong | - |
dc.contributor.author | Raja Sekhara Reddy, B. | - |
dc.contributor.author | Pratap Reddy Gajulapalli, V. | - |
dc.contributor.author | Sudhakar Babu, K. | - |
dc.contributor.author | Kim, Eunha | - |
dc.contributor.author | Lee, Sanghee | - |
dc.date.issued | 2020-12-15 | - |
dc.identifier.uri | https://dspace.ajou.ac.kr/dev/handle/2018.oak/31636 | - |
dc.description.abstract | Type I Interferon (IFN) signaling plays an important role in the immune defense system against virus infection and in the innate immune response, thus IFNs are widely used as anti-viral agents and treatment for immune disorder or cancer. However, there is a growing demand for novel small-molecule IFN inducer due to tolerance, toxicity, or short duration of action following direct administration of IFNs. In this study, we assessed arylpiperazine (ARP) as a new core skeleton of IFN inducer. To investigate structure–activity relationship, we designed and synthesized a series of ARP analogues and evaluated the ability to stimulate IFN response in THP-1 human monocyte cells. Compound 5i was identified as a potent type I IFN inducer as it significantly increased cytokine secretion and increased expression of various IFN-stimulating genes which are representative biomarkers of type I IFN pathway. Our results suggested a beneficial therapeutic potential of 5i as an anti-viral agent. | - |
dc.description.sponsorship | This study was financially supported by Korea Institute of Science and Technology (KIST) Institutional Program (2E30180) and Bio & Medical Technology Development Program (NRF-2019M3E5D4066905) of the National Research Foundation funded by Korean government (MSIT), a grant from Priority Research Centers Program (2019R1A6A1A11051471), 2020R1C1C1010044 funded by the National Research Foundation of Korea (NRF) and Convergence brain research through cross-institute collaboration (KBRI 20-BR-03-01/ IBS-R001-D1-2020-b02). | - |
dc.description.sponsorship | This study was financially supported by Korea Institute of Science and Technology (KIST) Institutional Program (2E30180) and Bio & Medical Technology Development Program (NRF-2019M3E5D4066905) of the National Research Foundation funded by Korean government (MSIT), a grant from Priority Research Centers Program (2019R1A6A1A11051471), 2020R1C1C1010044 funded by the National Research Foundation of Korea (NRF) and Convergence brain research through cross-institute collaboration (KBRI 20-BR-03-01/ IBS-R001-D1-2020-b02). | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Ltd | - |
dc.subject.mesh | Drug Design | - |
dc.subject.mesh | Humans | - |
dc.subject.mesh | Immunity, Innate | - |
dc.subject.mesh | Interferon Inducers | - |
dc.subject.mesh | Interferon Type I | - |
dc.subject.mesh | Monocytes | - |
dc.subject.mesh | Piperazines | - |
dc.subject.mesh | THP-1 Cells | - |
dc.title | Design, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers | - |
dc.type | Article | - |
dc.citation.title | Bioorganic and Medicinal Chemistry Letters | - |
dc.citation.volume | 30 | - |
dc.identifier.bibliographicCitation | Bioorganic and Medicinal Chemistry Letters, Vol.30 | - |
dc.identifier.doi | 10.1016/j.bmcl.2020.127613 | - |
dc.identifier.pmid | 33075488 | - |
dc.identifier.scopusid | 2-s2.0-85094216931 | - |
dc.identifier.url | http://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry-letters/ | - |
dc.subject.keyword | Anti-viral agent | - |
dc.subject.keyword | Arylpiperazine | - |
dc.subject.keyword | Innate immunity | - |
dc.subject.keyword | Interferon inducer | - |
dc.subject.keyword | type I Interferon | - |
dc.description.isoa | true | - |
dc.subject.subarea | Biochemistry | - |
dc.subject.subarea | Molecular Medicine | - |
dc.subject.subarea | Molecular Biology | - |
dc.subject.subarea | Pharmaceutical Science | - |
dc.subject.subarea | Drug Discovery | - |
dc.subject.subarea | Clinical Biochemistry | - |
dc.subject.subarea | Organic Chemistry | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.